The Latest Breaking News from Novavax

European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis. AbbVie shares traded in a range of $150.33 to $153.56 on a day volume…

Adults who haven't gotten any COVID-19 shots should consider the new option, the agency said Tuesday. The spike protein vaccine is more typical than the mRNA types being broadly used against COVID.

Despite the FDA authorization of Novavax’s (NVAX) two-dose vaccine, the possible side effects and slow vaccine uptake keep the stock under pressure. So, let’s evaluate if it is worth adding the stock to one’s portfolio now. Read on….

Australia has used less than a quarter of the hundreds of millions of COVID-19 vaccine doses it bought. What will happen to the rest?

Shares of Novavax (NASDAQ: NVAX) fell 26.2% on Jul 14, after the European Medicines Agency's (TSE: EMA) Pharmacovigilance Risk Assessment Committee ("PRAC") updated the product label of Nuvaxovid, the company's COVID-19 vaccine, to include some potential side effects like severe aller

The producer price index jumped 11.3% in June from the same period a year ago.

Here's a roundup of top developments in the biotech space over the last 24 hours:

CNBC United Airlines, Pilots’ Union To Improve Agreement By Renegotiating

Novavax Inc.’s COVID-19 vaccine was cleared by U.S. regulators, giving Americans another tool against the virus as cases start to rise again.